Skip to main content

CORRECTION article

Front. Endocrinol.
Sec. Obesity
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1528628

Editorial: Mechanistic insight and therapeutic potential for the management of non-alcoholic steatohepatitis (NASH)

Provisionally accepted
Dr Uma Shanker Navik Dr Uma Shanker Navik *Amit Khurana Amit Khurana Jasvinder Singh Bhatti Jasvinder Singh Bhatti
  • Central University of Punjab, Bathinda, India

The final, formatted version of the article will be published soon.

    progression in populations exposed to chronic hypoxia, such as those living at high Predictive tools that can identify nonobese people with NAFLD remain under investigation (Zheng et al.). However, rigorous studies will prospectively evaluate any novel index against validated measures longitudinally. Further studies are required, with careful anthropometric estimates that consider body fat distribution through accepted and validated anthropometric estimates of central obesity, such as waist circumference. Qiu et al. present a gender-focused analysis comparing the associations between liver enzyme markers alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) and NAFLD. Their study reveals significant gender-specific differences in the correlation between these enzymes and NAFLD, with ALT emerging as a particularly effective marker for screening the disease, especially in males. This finding underscores the accuracy of NAFLD screening, as it suggests that gender-specific approaches may enhance diagnostic effectiveness. The research highlights the need to consider gender-specific approaches during screening of NAFLD. Lastly, Wang et al. investigate the serum levels of glucose and albumin as their ratio (glucose-to-albumin ratio, GAR) relationship with NAFLD and its progression in non-diabetic individuals. Their work demonstrates a positive correlation between higher GAR and increased NAFLD risk, along with its progression into liver fibrosis. This research highlights GAR as a promising prognostic marker for identifying NAFLD and predicting disease progression, providing an important tool for early diagnosis and management of NAFLD.Together, these articles emphasize the growing body of knowledge around metabolic disorders, and the critical markers that can aid in early diagnosis, treatment, and management. With new insights into sex-specific treatments, hypoxia-induced liver damage mechanisms, and novel predictive indices, these research advances our understanding of NAFLD and related metabolic dysfunctions, offering fresh perspectives for the early diagnosis and therapeutic strategies, which could significantly improve outcomes for individuals at the risk of onset of NAFLD.

    Keywords: Non-alcoholic steatohepatitis (NASH), Genistein, Yes-associated Protein (YAP), Liver enzyme markers, glucose-to-albumin ratio

    Received: 15 Nov 2024; Accepted: 18 Nov 2024.

    Copyright: © 2024 Navik, Khurana and Bhatti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dr Uma Shanker Navik, Central University of Punjab, Bathinda, India

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.